Alnylam Pharma (ALNY) Misses Q2 EPS by 42c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $247.92 -1.48%
EPS Growth %: -39.0%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -39.0%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($2.03), $0.42 worse than the analyst estimate of ($1.61). Revenue for the quarter came in at $224.82 million versus the consensus estimate of $255.87 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- General Mills beats estimates as cost savings offset volumes
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
